Statements (48)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
drug
|
| gptkbp:activeDuring |
eliglustat
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:availability |
prescription only
|
| gptkbp:brand |
gptkb:Cerdelga
|
| gptkbp:chemicalFormula |
C22H30F2N2O4S
|
| gptkbp:clinicalTrials |
Phase 3
long-term treatment improved hematological parameters reduced liver volume reduced spleen volume |
| gptkbp:community_service |
available
|
| gptkbp:contraindication |
severe hepatic impairment
strong CYP2D6 inhibitors |
| gptkbp:dosageForm |
100 mg
200 mg |
| gptkbp:drugInterdiction |
highly protein-bound
CYP3A4 inhibitors CYP3A4 inducers CYP2D6 substrates |
| gptkbp:formulation |
capsule
|
| gptkbp:hasPopulation |
children
adults |
| https://www.w3.org/2000/01/rdf-schema#label |
Cerdelga
|
| gptkbp:isA |
3D1B1D1D1D
|
| gptkbp:mandates |
Type 1 Gaucher disease
|
| gptkbp:manufacturer |
Genzyme Corporation
|
| gptkbp:marketedAs |
2014
|
| gptkbp:marketSegment |
adverse events reported
|
| gptkbp:numberOfStudents |
about 30 hours
|
| gptkbp:nutritionalValue |
CYP2D6
|
| gptkbp:offers |
varies by region
|
| gptkbp:operates_in |
A16AX05
|
| gptkbp:packaging |
bottle
|
| gptkbp:R&D |
58468-001
|
| gptkbp:route |
oral
|
| gptkbp:safetyFeatures |
generally well tolerated
|
| gptkbp:sideEffect |
fatigue
headache nausea abdominal pain diarrhea |
| gptkbp:storage |
room temperature
|
| gptkbp:triggerType |
substrate reduction therapy
|
| gptkbp:type |
eliglustat
|
| gptkbp:usedFor |
gptkb:Gaucher_disease
|
| gptkbp:waterManagement |
urine
feces |